Joseph M. Raffaele, MD

Founder and Chief Medical Officer

Joseph Raffaele received his BA in philosophy from Princeton University and his MD from Hahnemann University Medical School in 1989. Dr. Raffaele did his residency at The New York Hospital/Cornell University Medical Center and was formerly a clinical assistant professor of medicine at Dartmouth Medical School while in practice at the Hitchcock Clinic. Dr. Raffaele is a member of the American College of Physicians, is board certified in internal medicine, and is a diplomat of the American Board of Age management Medicine.

In 1995 Dr. Raffaele began researching and developing a scientifically-based treatment program and co-founded PhysioAge Medical Group. Since 1997 Dr. Raffaele has been focused on age management medicine and biomarkers of aging. As CEO of PhysioAge, Dr. Raffaele developed the combination of biomarkers currently in use and has worked with Dr. Kumm to develop PhysioAge formula.

Johnathon Wright

Chief Technology Officer

Johnathon Wright is a senior software engineer and our technical lead. He has over 15 years of experience developing applications for the web. He has been working with PhysioAge since 2010.

He received a degree in Computer Science from the University of Louisiana, one of the top computer science schools in the South. Later, Johnathon was honored to work at ThoughtWorks, one of the most respected global software consultancies. Like all new ThoughtWorkers, Johnathon spent two weeks in India being indoctrinated into the Agile philosophy. He says he learned more there every day than in two weeks at any other job.

After leaving ThoughtWorks, Johnathon worked as a freelance developer for clients across the globe. He was honored to be offered a contract as NASA as a subject matter expert in Ruby on Rails.

Johnathon presents to local technology groups, serves as Treasurer on the board of the Vermilionville Living History Museum Foundation, and enjoys photography, working on his 1979 MGB, fishing, and writing more software. Although writing solid software is his specialty and passion, Johnathon says his biggest priority on this project, after preventing the release of PHI, is to examine the user interface phenomenologically. He likes big words.

Jerry Fortunato, MBA

Advisory Board

Jerry Fortunato received his BS in Finance from Rutgers University and his MBA from Rutgers Business School. He is a Project Management Professional and holds a certificate in E-Business from Baruch College. He spent 10 years with AT&T, where he was responsible for a $4.2B product line for mid-sized businesses. Prior to joining PhysioAge, Jerry directed Product Development at a Madrid-based software company focused on the IT needs of airlines.

Jerry joined PhysioAge Medical Group in 2002, where he was responsible for managing all business operations: business strategy, marketing & branding, finance, product management, patient relationship management, systems design & development and information technology support.

Michael B. Fossel, MD, PhD

Advisory Board

Michael Fossel received a PhD and MD at Stanford, where he had an NSF Fellowship, taught for several years, and studied aging and progeria. He was a Clinical Professor of Medicine at Michigan State University for almost three decades and currently teaches the Biology of Aging at Grand Valley State University. He founded the Journal of Anti-Aging Medicine (now Rejuvenation Research), and has published several dozen articles in JAMA, In Vivo, and other journals.

In 1996, he published Reversing Human Aging, explaining the telomere theory of aging, which was reviewed favorably in Scientific American and has been translated in 6 languages. He has appeared on Good Morning America, ABC 20/20, NBC Extra, Fox Network, CNN, BBC, Discovery Channel, and regularly on NPR.

His magisterial textbook, Cells, Aging, and Human Disease, was published in 2004 by Oxford University. With over four thousand references, it reviews the entire fields of telomere biology and cell senescence as they apply to human clinical disease as well as the potential for treating these diseases using telomerase therapy.

His newest book, The Telomerase Revolution, (which is already selling well in pre-orders on Amazon) will be published in October 2015 and explains the aging process, age-related diseases, and the upcoming human clinical trials of telomerase therapy. His new biotech company, Telocyte, is aimed at curing Alzheimer's disease.